Search
Menu
Home
HTB
2005
September
September 2005
Contents
Editorial
Volume 6 Number 9 September 2005
Conference reports
3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil
Adult male circumcision reduces transmission rates over 18 months comparable to a vaccine with 65% efficacy
Benefits of adding 4 or 7 days of AZT/3TC to single-dose nevirapine to prevent MTCT: further analysis from TOPS
New drugs in pregnancy: atazanavir; T20
Lopinavir/r use in children less than two years old promising results despite low plasma levels
Favourable outcomes in children treated with HAART in the MSF programmes
Encouraging results with cut up generic fixed dose combination tablets in Uganda
Predictors of survival at three years follow up for HIV-infected children in Cote D’Ivoire
Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results
T20 (enfuvirtide) studies presented at Rio
Strategies for salvage therapy
Antiviral activity of foscarnet in salvage patients
Novel strategies with existing drugs
Antiretroviral activity of new and novel agents
Overview of pharmacology studies
Incidence of TB infection despite HAART and treatment in coinfected patients
Evaluation of ESAT-6 and CFP-10 as markers for response to TB treatment in HIV/TB coinfected patients
Does WHO clinical stage reliably predict who should receive ARV treatment?
Continuous vs intermittent treatment with triple nuke combination of AZT/3TC/tenofovir in Africa: early results from DART study
Treatment access
Global Fund commitment to $175M annually in 2006, 2007
Pregnancy
US Preventative Services Task Force recommends screening all pregnant women for HIV
Guidelines
UK treatment guidelines online (2005)
Side effects
EMEA statement on metabolic and cardiovascular complications of antiretroviral therapy in HIV-infected patients
EMEA statement on use of antiretroviral treatment in HIV-patients with hepatic impairment and/or HBV/HCV co-infection
Other news
Volume 6 Number 9 September 2005 PDF
HTB RSS
Early access
Long-acting injectable PrEP approved in the US: priced at $28,000 a year
28 June 2025
Clinical studies of two once-weekly pipeline compounds put on hold
27 June 2025
UK HIV care for transgender and non-binary people: comment on unworkable EHRC guidelines by 30 June
26 June 2025
UK guidelines on doxyPEP to prevent syphilis
17 June 2025
All early access reports
Current issues
June 2025
May 2025
April 2025
Back issues
Special report
UK HIV care for transgender and non-binary people: comment on unworkable EHRC guidelines by 30 June
26 June 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate